Study of factors that affect muscle laminopathy with LMNA changes
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This study looks at what influences the course of a muscle disease caused by an LMNA genetic change (a type of laminopathy). It may help researchers better understand the disease and how it affects muscle and sometimes breathing or heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an LMNA gene mutation that has been linked to a laminopathy affecting striated (skeletal) muscle
- You currently have disease symptoms like muscle weakness and/or tendon shortening, with or without breathing or heart involvement
- You can safely have a muscle and skin biopsy (no major allergy to latex/skin antiseptics/local numbing medicine/adhesive dressings, and no bleeding-clotting problems that would make biopsy unsafe)
- If you take blood thinners or medicines that affect bleeding, this must be compatible with the study’s biopsy safety rules
- You can sign informed consent (or a parent/guardian can for a minor, following the rules)
- You are covered by the French health system (general French social security, CMU, or a similar French plan)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have a confirmed harmful (pathogenic) mutation in the LMNA and/or EMD gene. It aims to better understand these conditions through regular follow-up and health information collection, which may help improve future care.
This study looks at a molecule called miR-1 in the blood to see if it can help understand muscle diseases. Researchers will compare levels in people with certain muscle conditions and in healthy volunteers.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
This study looks at leftover muscle tissue from people who have had genetic testing for rare muscle diseases but didn't get a clear diagnosis. The goal is to use newer genetic analysis to find the cause of their disease.
Hear when a new Laminopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.